Lineage announces acquisition of NeuroAirmid Therapeutics
LCTX•Lineage Cell Therapeutics acquired NeuroAirmid Therapeutics and rights to its HUNT1 program for Huntington’s disease. NeuroAirmid shareholders will receive $4.70 million at closing and may receive up to $53 million total; Lineage expects to assume $3.10 million in clinical development costs through February 2030.
1. Acquisition terms
The acquisition includes rights to the REGEN4HD Phase 1b/2a trial for Huntington’s disease. NeuroAirmid shareholders will receive $4.70 million at closing and are eligible for up to $53 million total, while Lineage will assume estimated clinical development costs of $3.10 million through February 2030.
